Obesity Market Growth Opportunities

DelveInsight's Obesity Market Insights report offers a comprehensive understanding of current treatment practices, emerging drugs, market share of individual therapies, and the current and forecasted market size from 2020 to 2034, segmented into the 7MM (the United States, EU4 countries, the United Kingdom, and Japan). This article delves into the key takeaways from the report, the epidemiological landscape, treatment approaches, and the future outlook for the obesity market.

Request for Sample report @ Obesity Market

Key Takeaways from the Obesity Market Report

According to DelveInsight's analysis:

The obesity market size in the US was USD 1.2 billion in 2022.
In 2023, the total prevalent population of obesity in the United States was 114 million cases, expected to increase by 2034.
Leading companies like Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Eli Lilly and Company, Rhythm Pharmaceuticals, Inc., ACADIA Pharmaceuticals Inc., Harmony Biosciences, LLC, and Soleno Therapeutics, Inc. are developing novel obesity drugs set to enter the market in the coming years.
Prominent therapies in the pipeline include Oral semaglutide, Danuglipron (PF-06882961), Survodutide (BI 456906), Liraglutide, Cagrilintide, Orforglipron, Setmelanotide, Carbetocin, Pitolisant, and DCCR.
Recent FDA approvals, such as Eli Lilly and Company's ZEPBOUND (tirzepatide) and Pfizer's Phase IIb clinical trial success for danuglipron, underscore significant advancements in obesity treatment.

Obesity Overview

Obesity is recognized as a chronic condition characterized by excessive body fat and is influenced by genetic predisposition and environmental factors. Severe and early-onset obesity often results from genetic mutations affecting the leptin-melanocortin pathway. Symptoms include high blood pressure, stretch marks, and a body mass index (BMI) exceeding 30 kg/m², increasing the risk of various diseases.

Epidemiology

DelveInsight's report indicates a rising trend in diagnosed obesity cases, with the US accounting for a significant portion of these cases. The epidemiological analysis covers:

Total Prevalent Cases of Obesity
Total Obesity Patients Seeking Help
Total Treated Cases of Obesity

Obesity Treatment Market

Treatment for obesity primarily involves weight reduction through diet, physical activity, and lifestyle changes. However, some individuals may require alternative therapies such as weight-loss medications, devices, or bariatric surgery. Emerging treatment methods include:

Hydrogels: Ingestible capsules that absorb water in the stomach, creating a sense of fullness.
Vagal Nerve Blockade: An implanted device that sends electrical signals to the vagus nerve, signaling fullness to the brain.
Gastric Aspirate: A surgical procedure that removes a portion of stomach contents post-meal.

FDA-Approved Treatments

The obesity treatment market includes several FDA-approved medications:

CONTRAVE (bupropion-naltrexone): Reduces appetite and cravings.
SAXENDA (liraglutide): An injectable that curbs appetite and slows stomach emptying.
Alli and XENICAL (orlistat): Blocks pancreatic lipase to aid in weight management.
QSYMIA (phentermine-topiramate): Suppresses appetite and promotes weight loss.
IMCIVREE (setmelanotide): Approved for genetic-based obesity.
WEGOVY (semaglutide): An injectable drug that supports weight loss when combined with a reduced-calorie diet and increased physical activity.

Pipeline Therapies and Key Companies

Several promising therapies are in the pipeline, including:

Oral semaglutide (Novo Nordisk): Approved for glycemic control in type II diabetes and under development for obesity treatment.
Danuglipron (PF-06882961) (Pfizer): An oral GLP-1 receptor agonist showing significant weight reduction in clinical trials.
Survodutide (BI 456906) (Boehringer Ingelheim), Liraglutide (Novo Nordisk A/S), Cagrilintide (Novo Nordisk A/S), Orforglipron (Eli Lilly and Company), Setmelanotide (Rhythm Pharmaceuticals, Inc.), Carbetocin (ACADIA Pharmaceuticals Inc.), Pitolisant (Harmony Biosciences, LLC), DCCR (Soleno Therapeutics, Inc.): These therapies are in various stages of development and are expected to transform the obesity market.

Request for Sample report @ Obesity Market

Market Dynamics

The obesity market is poised for significant changes driven by:

Increased investment in drug research and development.
Advancements in mobile technologies for understanding and intervening in obesity.
Initiatives by pharmaceutical companies like Novo Nordisk and Eli Lilly and Company to address unmet needs in the obesity market.
Efforts by governmental and nongovernmental bodies to raise awareness and expand treatment options.

Growth Drivers

The anticipated launch of emerging therapies with improved efficacy, better diagnosis rates, and increased patient awareness are expected to drive market growth. As new therapies gain regulatory approval, they will set new standards of care, fostering medical innovation and economic growth.

Challenges

Several factors could impede market growth, including:

Lack of consensus on the best obesity treatment.
Disparities in disease staging systems.
Complications from comorbidities associated with obesity.
High economic burden and impact on quality of life.
Failures and discontinuations of emerging therapies.
Market access and reimbursement issues.
Shortage of healthcare specialists and unawareness about the disease.

Conclusion

The obesity market presents substantial growth opportunities driven by advancements in treatment options, a growing prevalence of obesity, and increased investment in research and development. Despite challenges, the market is expected to expand significantly during the forecast period, transforming the landscape of obesity treatment and offering new opportunities for medical innovation and economic growth. As emerging therapies mature and gain regulatory approval, they are set to reshape the obesity market, providing patients with more effective treatment options and improving overall health outcomes.

Trending Reports:

DelveInsight: